Procter & Gamble
This article was originally published in The Rose Sheet
Company confirms its sales and earnings guidance for the second quarter of fiscal year 2007, projecting sales growth of 5%-8% and organic sales growth of 4%-7%. The company will announce final results for the quarter Jan. 30, 2007. Q1 revenue increased 11% to $5.6 bil. due to growth across all categories, P&G said during Dec. 14 analyst call. Organic sales volume in the skin care division was up double digits, driven by the launch of Olay Definity and the performance of OlayRegenerist (1"The Rose Sheet" Nov. 6, 2006, p. 8)...
You may also be interested in...
Procter & Gamble beauty division revenues increased 11% to $5.6 bil. for the first quarter of fiscal year 2007 (ended Sept. 30), fueled by growth across all categories and the addition of Gillette products, the company reported in an Oct. 31 earnings release
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.